GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Travere Therapeutics Inc (NAS:TVTX) » Definitions » Intangible Assets

Travere Therapeutics (Travere Therapeutics) Intangible Assets : $104.5 Mil (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Travere Therapeutics Intangible Assets?

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Travere Therapeutics's intangible assets for the quarter that ended in Dec. 2023 was $104.5 Mil.


Travere Therapeutics Intangible Assets Historical Data

The historical data trend for Travere Therapeutics's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Travere Therapeutics Intangible Assets Chart

Travere Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intangible Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 158.14 154.13 148.40 97.12 104.49

Travere Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 97.12 162.88 154.42 106.95 104.49

Travere Therapeutics Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.


Travere Therapeutics  (NAS:TVTX) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


Travere Therapeutics Intangible Assets Related Terms

Thank you for viewing the detailed overview of Travere Therapeutics's Intangible Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Travere Therapeutics (Travere Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
3611 Valley Centre Drive, Suite 300, San Diego, CA, USA, 92130
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
Executives
Jula Inrig officer: Chief Medical Officer C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
Peter Heerma officer: Chief Commercial Officer C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
William E. Rote officer: Senior Vice President, R&D C/O RETROPHIN, INC., 3721 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130
Christopher R. Cline officer: Chief Financial Officer C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, STE 300, SAN DIEGO CA 92130
Eric M Dube director, officer: Chief Executive Officer 3721 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130
Elizabeth E Reed officer: SVP, GC & Corporate Secretary 9050 CAMINO SANTA FE, SAN DIEGO CA 92121
Sandra Calvin officer: VP, Corp Controller and CAO 3611 VALLEY CENTER DRIVE, SUITE 300, SAN DIEGO CA 92130
Laura Clague officer: Chief Financial Officer 370 PARK RANCH PLACE, ESCONDIDO CA 92025
Steve Aselage director 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Brinkley Ruth Williams director C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
Noah L. Rosenberg officer: Chief Medical Officer C/O ESPERION THERAPEUTICS, INC., 46701 COMMERCE CENTER DRIVE, PLYMOUTH MI 48170
Suzanne Louise Bruhn director C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Neil F. Mcfarlane officer: Chief Operating Officer C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Sandra Poole director 830 WINTER STREET, WALTHAM MA 02451
Ron Squarer director C/O ADC THERAPEUTICS SA, BIOPOLE, ROUTE DE LA CORNICHE 3B, EPALINGES V8 1066

Travere Therapeutics (Travere Therapeutics) Headlines

From GuruFocus